Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers
Crossref DOI link: https://doi.org/10.1007/s40271-015-0139-7
Published Online: 2015-09-14
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
MacLeod, Tatjana E.
Harris, Anthony H.
Mahal, Ajay
Text and Data Mining valid from 2015-09-14